PharmacoEconomics

Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: A NICE Single Technology Appraisal
pp. 439-448(10)
Authors: Bagust, Adrian; Greenhalgh, Janette; Boland, Angela; Fleeman, Nigel; McLeod, Claire; Dickson, Rumona; Dundar, Yenal; Proudlove, Christine; Shaw, Richard

Methodological Concerns with Economic Evaluations of Meningococcal Vaccines
pp. 449-461(13)
Author: Kauf, Teresa L.

Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia?
pp. 463-475(13)
Authors: Chim, Lesley; Kelly, Patrick J.; Salkeld, Glenn; Stockler, Martin R.

Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis
pp. 477-487(11)
Authors: Adams, Roisin; Walsh, Cathal; Veale, Douglas; Bresnihan, Barry; FitzGerald, Oliver; Barry, Michael

Cost Effectiveness of 5-Alpha Reductase Inhibitors for the Prevention of Prostate Cancer in Multiple Patient Populations
pp. 489-505(17)
Authors: Earnshaw, Stephanie R.; McDade, Cheryl L.; Black, Libby K.; Bell, Christopher F.; Kattan, Michael W.

Does the Inclusion of a Cost Attribute Result in Different Preferences for the Surgical Treatment of Primary Basal Cell Carcinoma?: A Comparison of Two Discrete-Choice Experiments
pp. 507-520(14)
Authors: Essers, Brigitte A.B.; >Debby van Helvoort-Postulart,; Prins, Martin H.; Neumann, Martino; Dirksen, Carmen D.